Atara Biotherapeutics Inc (ATRA) USD0.0001

Sell:$6.00Buy:$6.02$0.17 (2.86%)

NASDAQ:0.87%
Market closed | Prices delayed by at least 15 minutes
Sell:$6.00
Buy:$6.02
Change:$0.17 (2.86%)
Market closed | Prices delayed by at least 15 minutes
Sell:$6.00
Buy:$6.02
Change:$0.17 (2.86%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.

Key people

Pascal Touchon
Chairman of the Board
Anhco Nguyen
President, Chief Executive Officer, Director
Jill Henrich
Executive Vice President - Global Head Regulatory Affairs and Quality
Carol G. Gallagher
Lead Independent Director
Gregory A. Ciongoli
Independent Director
Matthew K. Fust
Independent Director
William K. Heiden
Independent Director
Ameet Mallik
Independent Director
Click to see more

Key facts

  • EPIC
    ATRA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0465132068
  • Market cap
    $34.80m
  • Employees
    153
  • Shares in issue
    5.86m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.